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Introduction
Status epilepticus (SE) is a life-threatening medical emergency that consists 
of persistent or recurring seizures that require prompt intervention in children. 
Prolonged and uncontrolled refractory status epilepticus is associated with high 
mortality and morbidity, and its prognosis is dependent on the management of the 
underlying condition and on the treatment of seizures (1,2,3,4,5).
Care involves the termination of seizures and the identification and management of 
any underlying conditions. 
There is no consensus on the optimal therapy for refractory status epilepticus, but 
there is increasing published experience with multiple medications and treatment 
strategies, such as high-dose phenobarbital ketamine, midazolam, thiopental, and 
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Abstract
Objective
Prolonged and uncontrolled refractory status epilepticus (SE) is a life-threatening 
medical emergency in children (1,2,3). There is no consensus on the optimal 
therapy for refractory status epilepticus (1). The aim of this study was to develop 
a new method for treating patients with refractory status epilepticus.
Materials & Methods
Ten children with refractory status epilepticus in Mofid Hospital, who did not 
respond to 10 µg/kg per min of intravenous midazolam, had their dose of 
midazolam increased to 30 µg/kg per min. All children were monitored for the 
development of side effects.
Results
Ten children with no response to low-dose midazolam were given a higher 
dose of midazolam, and 5 (50%) children had a good response. These patients 
had significantly different response to high-dose midazolam.
One patient in the high-dose midazolam group was intubated and required 
mechanical ventilation. The duration of stay in the hospital and PICU and on 
mechanical ventilation in patients with no response to low-dose midazolam 
following with other drugs was longer than in the high-dose midazolam group.
No death occurred in high dose midazolam group.
Conclusion
High-midazolam dose drip infusion is a safe and effective protocol for refractory 
status epilepticus in children.
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propofol (1). Midazolam has remarkable anticonvulsant 
activity, and several clinical reports have described 
the successful use of midazolam for refractory SE in 
children using different doses and methods (1,4-11). 
The mechanism of midazolam involves the modulation 
of GABA type A receptors, which suppresses neuronal 
excitability (12). The conventional midazolam dose in 
most studies and in Mofid Children Hospital is an initial 
bolus of 0.1-0.2 mg/kg, followed by an infusion of 1-2 
µg/kg/min that is increased as needed to 7-10 µg/kg/min. 
In some studies, midazolam was increased as needed to 
20-30 µg /kg/min(1, 4, 10). These studies suggest that a 
greater increase is associated with more prompt seizure 
control. 
The aim of this study was to develop a new method for 
treating patients with refractory status epilepticus and 
investigate the efficacy and side effects of a high-dose 
(to 30 µg/kg/min) midazolam infusion in childhood 
refractory status epilepticus compared with low-dose 
midazolam.
 
Materials & Methods 
This study included children with refractory status 
epilepticus who were admitted to Mofid Hospital, aged 
1 month to less than 16 years, from October 2008 to May 
2010.
In patients with status epilepticus, if seizures 
persisted despite treatment with adequate doses of 2 
or 3 anticonvulsant medications, the condition was 
considered refractory status epilepticus. 
All patients were transferred to the PICU, and midazolam 
was administered as an intravenous bolus dose (0.2 
mg/kg), followed by low-dose continuous intravenous 
infusion (1-10 µg/kg per min). In 10 children with no 
response to 10 µg/kg per min of intravenous midazolam, 
the dose of midazolam was increased by 1 µg/kg per min 
every 15 min until complete control of seizures or up to 
30 µg/kg per min.
All children were monitored for the development of 
side effects of midazolam, such as hypotension and 
respiratory depression. Routine laboratory examinations 
and EEGs were performed for all patients. Brain CT or 
MRI was performed if needed. 
Clinical data, including age, sex, seizure history, 
underlying etiology, and outcome, were carefully 
recorded for each patient.
We compared the 2 groups by independent sample t test, 
Fisher’s exact test, or Mann-Whitney U test. A value of 
P < 0.05 was regarded as significant.
Results
Our refractory status epilepticus groups comprised 24 
patients-11 boys and 13 girls (age range 7 months to 
12 years). Fourteen patients had neurodevelopmental 
disabilities, and 15 cases had a background of 
symptomatic or cryptogenic epilepsy.
Low-dose intravenous midazolam was given to 24 
patients. Eight (33, 3%) children had a good response 
to this dose of midazolam. Ten of 16 patients with no 
response to low-dose midazolam were treated with a 
higher dose of midazolam, and 6 patients were treated 
with other drugs, such as propofol and thiopental. In 
the high-dose midazolam group, 5 (50%) children had 
a good response. Patients with no response to low-dose 
midazolam had a significantly different response from 
those who were given high-dose midazolam (P= 0/010).
In the high-dose group, of the 5 patients with no response 
to midazolam, 4 children’s seizure were controlled by 
other anticonvulsant drugs. 
During admission to the hospital, 1 patient in the high-
dose midazolam group and 6 patients in the low-dose 
diazepam group (2 with good response and 4 who were 
treated with other medications, such as thiopental and 
propofol) were intubated and required mechanical 
ventilation (P= 0/081).
Fourteen children had symptomatic epilepsy (5 patients 
in the high-dose group), and 1 child in the high-dose 
group had cryptogenic epilepsy. 
 Bradycardia was seen in 1 child who was treated with 
high-dose midazolam, which resolved with a decrease 
in dose.
The duration of stay in the hospital and PICU and on 
mechanical ventilation in patients with no response to 
low-dose midazolam following with other drugs was 
longer than in the high-dose midazolam group (P=NS) 
(Table 1).
Five deaths occurred during treatment in patients with 
no response to low-dose midazolam that following with 
other medications, but it was difficult to judge the causal 
relationship between the mortalities and drugs. No 
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deaths occurred in the high-dose midazolam group.
In the high-dose midazolam group, 6 patients were 
discharged with complete control of their seizures, and 4 
patients had partial control. 
Discussion
The safety and efficacy of midazolam have been 
demonstrated in several clinical studies for acute seizures 
and status epilepticus in adult sand children (1,4-11).
In refractory status epilepticus, we found that if seizures 
failed to cease with continuous low-dose intravenous 
midazolam (10 µg/kg per/min), increasing the dose up 
to 30 µg/kg per/min was effective in half of the cases; 
further, this protocol is a safe method with a low side 
effect into other medications.
We recently showed that the adverse effects of high-dose 
midazolam do not exceed those of low-dose midazolam, 
nor do the duration of admission to the PICU and 
hospitalization and need for mechanical ventilation. 
Early termination of status epilepticus is important in 
preventing adverse consequences and reducing the risk 
of developing brain sequels (1-4).
A high midazolam dose drip infusion is a safe and 
effective protocol for refractory status epilepticus and 
does not require specific specialty to administration such 
as propofol and thiopental.
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